<DOC>
	<DOCNO>NCT02148640</DOCNO>
	<brief_summary>The purpose study assess safety efficacy switch Remicade biosimilar treatment Remsima patient rheumatoid arthritis , spondyloarthritis , psoriatic arthritis , ulcerative colitis , Crohn 's disease chronic plaque psoriasis</brief_summary>
	<brief_title>The NOR-SWITCH Study</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Spondylarthritis</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>1 . A clinical diagnosis either rheumatoid arthritis , spondyloarthritis , psoriatic arthritis , ulcerative colitis , Crohn 's disease chronic plaque psoriasis 2 . Male nonpregnant , nonnursing female 3 . &gt; 18 year age screen 4 . Stable treatment innovator infliximab ( Remicade ) last 6 month 5 . Subject capable understanding signing informed consent form 6 . Provision write informed consent 1 . Major comorbidities , severe malignancy , severe diabetic mellitus , severe infection , uncontrollable hypertension , severe cardiovascular disease ( NYHA class 3 4 ) and/or severe respiratory diseases 2 . Change major comedication last 2 month prior randomization : RA , SpA PsA : Initiation systemic corticosteroid synthetic DMARDs medication accord investigator would interfere stability disease . UC CD : Initiation systemic corticosteroid immunosuppressant medication accord investigator would interfere stability disease Psoriasis : Initiation synthetic DMARDs medication accord investigator would interfere stability disease 3 . Inadequate birth control , pregnancy , and/or breastfeed 4 . Psychiatric mental disorder , alcohol abuse substance abuse , language barrier factor make adherence study protocol impossible 5 . Change treatment innovator infliximab ( Remicade ) last 6 month due disease related factor , include dose/frequency adjustment due drug concentration measurement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>